Literature DB >> 23959845

Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Christopher J Carbone1, Serge Y Fuchs.   

Abstract

Activation of cytokine receptor-associated Janus kinases (JAKs) mediates most, if not all, of the cellular responses to peptide hormones and cytokines. Consequently, JAKs play a paramount role in homeostasis and immunity. Members of this family of tyrosine kinases control the cytokine/hormone-induced alterations in cell gene expression program. This function is largely mediated through an ability to signal toward activation of the signal transducer and activator of transcription proteins (STAT), as well as toward some other pathways. Importantly, JAKs are also instrumental in tightly controlling the expression of associated cytokine and hormone receptors, and, accordingly, in regulating the cell sensitivity to these cytokines and hormones. This review highlights the enzymatic and non-enzymatic mechanisms of this regulation and discusses the importance of the ambidextrous nature of JAK as a key signaling node that integrates the combining functions of forward signaling and eliminative signaling. Attention to the latter aspect of JAK function may contribute to emancipating our approaches to the pharmacological modulation of JAKs.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  CYTOKINE; DOWNREGULATION; JAK; KINASE; RECEPTOR

Mesh:

Substances:

Year:  2014        PMID: 23959845      PMCID: PMC3856693          DOI: 10.1002/jcb.24647

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  145 in total

1.  Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.

Authors:  Hui Zheng; Juan Qian; Darren P Baker; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2011-08-24       Impact factor: 5.157

2.  Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2.

Authors:  Pradeep Sathyanarayana; Arvind Dev; Anamika Pradeep; Melanie Ufkin; Jonathan D Licht; Don M Wojchowski
Journal:  Blood       Date:  2012-04-16       Impact factor: 22.113

3.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

4.  Phosphorylation of human gp130 at Ser-782 adjacent to the Di-leucine internalization motif. Effects on expression and signaling.

Authors:  R M Gibson; W P Schiemann; L B Prichard; J M Reno; L H Ericsson; N M Nathanson
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Determinants of growth hormone receptor down-regulation.

Authors:  Luqin Deng; Kai He; Xiangdong Wang; Ning Yang; Chellappagounder Thangavel; Jing Jiang; Serge Y Fuchs; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2007-05-08

6.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

7.  Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif.

Authors:  K G Suresh Kumar; Bentley Varghese; Anamika Banerjee; Darren P Baker; Stefan N Constantinescu; Sandra Pellegrini; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

8.  Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Toshiaki Hayashi; Masaharu Akiyama; Nicholas Mitsiades; Constantine Mitsiades; Klaus Podar; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

Review 9.  Tyrosine kinase 2 (TYK2) in cytokine signalling and host immunity.

Authors:  Birgit Strobl; Dagmar Stoiber; Veronika Sexl; Mathias Mueller
Journal:  Front Biosci (Landmark Ed)       Date:  2011-06-01

10.  Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells.

Authors:  A M Sinclair; N Rogers; L Busse; I Archibeque; W Brown; P D Kassner; J E V Watson; G E Arnold; K C Q Nguyen; S Powers; S Elliott
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

View more
  4 in total

1.  A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Authors:  Kang-Jian Zhang; Xiao-Fei Yin; Yuan-Qin Yang; Hui-Ling Li; Yan-Ni Xu; Lie-Yang Chen; Xi-Jun Liu; Su-Jing Yuan; Xian-Long Fang; Jing Xiao; Shuai Wu; Hai-Neng Xu; Liang Chu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Rong-Bing Guo; Guang-Wen Wei; Da-Cheng Wang; Xin-Yuan Liu; Serge Y Fuchs
Journal:  Clin Cancer Res       Date:  2016-09-28       Impact factor: 12.531

Review 2.  Molecular targets of luteolin in cancer.

Authors:  Muobarak J Tuorkey
Journal:  Eur J Cancer Prev       Date:  2016-01       Impact factor: 2.497

Review 3.  From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases.

Authors:  Dominika Hromadová; Dirk Elewaut; Robert D Inman; Birgit Strobl; Eric Gracey
Journal:  Front Genet       Date:  2021-07-05       Impact factor: 4.599

4.  Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.

Authors:  P Narayanan; T-K Man; R B Gerbing; R Ries; A M Stevens; Y-C Wang; X Long; A S Gamis; T Cooper; S Meshinchi; T A Alonzo; M S Redell
Journal:  Clin Transl Oncol       Date:  2021-05-04       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.